Ondansetron in the treatment of panic disorder
β Scribed by Franklin R. Schneier; Robin Garfinkel; Barbara Kennedy; Raphael Campeas; Brian Fallon; Randall Marshall; Lisa O'Donnell; Tony Hogan; Michael R. Liebowitz
- Publisher
- John Wiley and Sons
- Year
- 1996
- Tongue
- English
- Weight
- 362 KB
- Volume
- 2
- Category
- Article
- ISSN
- 1070-9797
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Ondansetron is a highly selective antagonist at the 5-HT 3 subtype of serotonin (5-HT) receptors . The 5-HT 3 receptors are the only receptors whose effects are mediated through the ion channels rather than the G-protein series . Ondansetron has no appreciable affinity for other 5-HT receptor subtyp
Ninety-three patients with panic disorder and mild or no agoraphobia were treated for their panic disorder by using either 11 sessions of individual cognitive-behavior therapy or imipramine. Before and after treatment, their panic disorder symptomatology was assessed, and a self-report measure was a
Three drugs are currently licensed for the treatment of panic disorder: the benzodiazepine, alprazolam; the tricyclic antidepressant, clomipramine; and, most recently, the selective serotonin reuptake inhibitor, paroxetine. Alprazolam and clomipramine are eective in the treatment of panic disorder,
## A long-standing debate has raged about the relative efficacy of pharmacotherapy and focal psychotherapies (e.g., cognitive and behavioral therapies) in the treatment of panic disorder. Though the controversy continues unabated, data have begun to accumulate which suggest that the focal psychother
By using data from the Bremer Adolescent Study, this report presents findings on the frequency, comorbidity, and psychosocial impairment of panic disorder and panic attacks among 1,035 adolescents. The adolescents were randomly selected from 36 schools in the province of Bremen, Germany. Panic disor